Consensus Report
Metformin
Moderate Consensus
out of 5
Based on 44 videos (68 hours analyzed) across the experts · Updated 2026-03-23
Expert Positions
The Verdict
Metformin is the most debated longevity drug among the 5 experts. Attia has extensively covered it across 27+ videos but shifted from cautious optimism to skepticism, concluding it may be a mitochondrial toxin for healthy individuals. Huberman explicitly avoids it for longevity. Hyman acknowledges it as the safest diabetes drug but favors lifestyle interventions over pharmacological approaches. Patrick has minimal coverage. Johnson includes metformin in his Blueprint protocol but is discussed only via Hyman's channel.
Where They Disagree
Attia fundamentally shifted from cautious optimism to active skepticism about metformin for longevity in healthy individuals, while Barzilai (a frequent guest on Attia's show) continues to champion it through the TAME trial as a geroprotective agent.
Huberman avoids metformin entirely for longevity, citing insufficient human data, while Johnson actively takes it as part of his Blueprint protocol based on his data-driven approach.
+ 3 more disagreements in the full report
About This Analysis
This consensus report on Metformin is based on 44 videos (68 hours analyzed) from five longevity experts: Andrew Huberman, Peter Attia, Rhonda Patrick, Bryan Johnson, and Mark Hyman. Each expert's position was independently analyzed from their published video content, including lectures, podcast episodes, and Q&A sessions with 1,000+ guest scientists.
The full report includes 9 key findings, dosage and protocol details, expert deep dives with direct video citations and timestamps, risk considerations, and related supplement synergies.
Frequently Asked Questions
What do experts agree on about metformin?
Metformin is the most debated longevity drug among the 5 experts. Attia has extensively covered it across 27+ videos but shifted from cautious optimism to skepticism, concluding it may be a mitochondrial toxin for healthy individuals.
Where do the experts disagree on metformin?
Attia fundamentally shifted from cautious optimism to active skepticism about metformin for longevity in healthy individuals, while Barzilai (a frequent guest on Attia's show) continues to champion it through the TAME trial as a geroprotective agent. Huberman avoids metformin entirely for longevity, citing insufficient human data, while Johnson actively takes it as part of his Blueprint protocol based on his data-driven approach. Hyman frames metformin as the safest diabetes drug and acknowledges AMPK activation, but concludes lifestyle interventions outperform it — contrasting with Sinclair (guest on both Huberman and Hyman shows) who personally takes metformin daily as part of his anti-aging regimen.
How strong is the expert consensus on metformin?
The consensus on metformin scores 2.5/5 — a moderate level of agreement across Huberman, Attia, Patrick, Johnson, and Hyman, based on their public videos.
Related Reports
Unlock the Full Report
Get dosages, timing protocols, expert deep dives with video citations, and risks for Metformin.
Every recommendation traces back to a specific expert, video, and timestamp.
$9/month or $79/year · Cancel anytime